| 产品描述: | VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CINHigh tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research. |
| 靶点: |
IC50: 9.4 nM (KIF18A microtubule-dependent ATPase activity) |
| 体外研究: |
VLS-1272 (Compound 22; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。 |
| 体内研究: |
VLS-1272 (Compound 22; 7 days) 抑制 JIMT-1、NIH-OVCAR3 和 HCC-15 细胞活力,IC50 分别为 0.0078、0.0097 和 0.011 μM。 |
| 参考文献: |
1. COGAN, et al. SPIRO INDOLINE INHIBITORS OF KIF18A. Patent WO2023028564. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.832 ml |
9.162 ml |
18.325 ml |
| 5 mM |
0.366 ml |
1.832 ml |
3.665 ml |
| 10 mM |
0.183 ml |
0.916 ml |
1.832 ml |
| 50 mM |
0.037 ml |
0.183 ml |
0.366 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |